Laboratoires Théa SAS
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
News
UK Issues Class 2 Recall for Zaditen Eye Drops Batch Due to Potential Microbial Contamination Risk
The UK's MHRA has issued a class 2 medicines recall for batch 4V64 of Zaditen 0.25 mg/ml eye drops solution due to a manufacturing event that may increase microbial contamination risk.
Kiora Pharmaceuticals Partners with Senju for KIO-301 Development in Asian Markets Worth Over $110 Million
Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option for KIO-301 development and commercialization rights across key Asian markets including Japan and China, with a total potential deal value of $110 million plus royalties.
Vevizye (Ciclosporin 0.1%) Receives European Commission Approval for Dry Eye Disease
• Novaliq and Laboratoires Théa secured European Commission approval for Vevizye (ciclosporin 0.1% eye drops) for moderate to severe dry eye disease. • Vevizye, utilizing Novaliq’s EyeSol technology, is the first water-free ciclosporin 0.1% eye drop approved in the EU for this condition. • Clinical trials (ESSENCE-1 and ESSENCE-2) demonstrated statistically significant reduction in corneal fluorescein staining with Vevizye treatment. • Laboratoires Théa will commercialize Vevizye in Europe and select MENA countries, expanding access to this innovative treatment.